Stories about Krankheit
- more
Press Release: STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
3 DocumentsmoreAsklepios Kliniken GmbH & Co. KGaA
Hessian Minister President Boris Rhein presents the Broermann Medical Innovation Award
Wiesbaden, Germany (ots) - - Dr. Carl June and Dr. Michel Sadelain honored for groundbreaking CAR-T cell research in cancer therapy - One of the world’s most highly endowed medical prizes, with €1 million in prize money, awarded for the first time - Titia große Broermann: “With the Broermann Medical Innovation Award, we want to make outstanding medical ...
moreEuropäischer Rechnungshof - European Court of Auditors
Μικρό το όφελος για τις επιχειρήσεις της ΕΕ από τα δισεκατομμύρια που διατέθηκαν για την ανάκαμψη από την πανδημία
moreEuropäischer Rechnungshof - European Court of Auditors
Koronapandemiasta toipumiseen osoitetuilla miljardeilla olisi voitu auttaa EU:n yrityksiä enemmänkin
moreEuropäischer Rechnungshof - European Court of Auditors
Coronamiljarderna kunde ha gjort mer för EU:s företag
more
Europäischer Rechnungshof - European Court of Auditors
Paransivatko koronapandemiasta toipumiseen osoitetut miljardit EU:n liiketoimintaympäristöä? (Kutsu tiedotustilaisuuteen)
Kutsu tiedotustilaisuuteen 27. lokakuuta 2025 Paransivatko koronapandemiasta toipumiseen osoitetut miljardit EU:n liiketoimintaympäristöä? - Tiedotustilaisuus verkossa maanantaina 27. lokakuuta klo 10 00 Keski-Euroopan aikaa ...
moreEuropäischer Rechnungshof - European Court of Auditors
Har alla miljarder som gått till återhämtningen efter covid förbättrat EU:s företagsklimat? (Pressinbjudan)
Pressinbjudan till den 27 oktober 2025 Har alla miljarder som gått till återhämtningen efter covid förbättrat EU:s företagsklimat? - Presskonferens online måndagen den 27 oktober kl. 10.00 CET. - Offentliggörande samma ...
moreLetter of Intent for strategic partnership / Vaccentis and TrueMed join forces to advance cancer vaccine
Zurich (ots) - Vaccentis, a Zurich based biotech company specializing in the development of therapeutic protein-based tumor vaccines, has signed a letter of intent with TrueMed, a leading commercialization partner. Accelerating cancer vaccine against renal cell carcinoma The aim of this letter of intent is to ...
moreMaP Toolbox: Your Hub for Master Protocol Clinical Trials
moreEuropäischer Rechnungshof - European Court of Auditors
Läkemedelsbristen är fortfarande en kronisk huvudvärk för EU
moreEuropäischer Rechnungshof - European Court of Auditors
(Presskonferens) Kan EU bota bristen på kritiska läkemedel?
Kan EU bota bristen på kritiska läkemedel? - Presskonferens online onsdagen den 17 september kl. 10.00 CEST. - Offentliggörande samma dag kl. 17.00 CEST. Europeiska revisionsrätten inbjuder härmed till en presskonferens online inför offentliggörandet av en särskild rapport om EU:s åtgärder för att säkerställa ...
more
Europäischer Rechnungshof - European Court of Auditors
(Ενημέρωση Τύπου) Μπορεί η ΕΕ να θεραπεύσει τις ελλείψεις σε φάρμακα κρίσιμης σημασίας;
Μπορεί η ΕΕ να θεραπεύσει τις ελλείψεις σε φάρμακα κρίσιμης σημασίας; - Διαδικτυακή ενημέρωση Τύπου: Τετάρτη 17 Σεπτεμβρίου, ...
moreEuropäischer Rechnungshof - European Court of Auditors
(Tiedotustilaisuus) Voiko EU löytää parannuskeinon lääkepulaan?
Voiko EU löytää parannuskeinon lääkepulaan? - Tiedotustilaisuus verkossa keskiviikkona 17. syyskuuta klo 10.00 Keski-Euroopan kesäaikaa - Kertomus julkaistaan samana päivänä klo 17.00 Keski-Euroopan kesäaikaa Euroopan tilintarkastustuomioistuin kutsuu teidät ...
moreServier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
moreTechnische Universität München
Slime as a material for multifunctional spheres
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Hollow microparticles for cargo molecules Slime as a material for multifunctional spheres - Hollow microspheres for molecular cargoes combine multiple functions - They adhere effectively to soft tissue and cartilage - Potential future applications in osteoarthritis or for oral ulcers Researchers at the Technical University of Munich (TUM) have developed hollow microspheres made ...
moreUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...
morePress release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
One documentmore
- 2
New Endoscopy Technology Enables Early Detection of Esophageal Cancer
more Technische Universität München
A new biotech hub for Munich
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE A new biotech hub for Munich Where science powers start-ups: Launching BioLabs|TUM • TUM Venture Labs cooperate with BioLabs and Lilly • 1,800 square meters of coworking lab space • Aiming at accelerating therapy development BioLabs, TUM Venture Labs, and Eli Lilly and Company (Lilly) today launched BioLabs|TUM, a new biotechnology innovation hub in central Munich. The initiative aims to empower early-stage biotech start-ups ...
moreTherapeutic Vaccine for Chronic Hepatitis B Enters First Clinical Trial in Patients
moreTherVacB: Advance Curative Strategy for Chronic Hepatitis B
moreCancer Cachexia: Liver Identified as Driver of Body Wasting
Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected, which further weakens the body. This wasting syndrome, known as cachexia, affects around half of all cancer patients. It is a major cause of therapy resistance, complications, and increased mortality. ...
moreWorld Health Summit 2025: Registration Open - First High-Level Speakers Announced
Berlin (ots) - Registration for the World Health Summit 2025 is now open. From October 12-14, Berlin will once again host one of the most important strategic global health gatherings worldwide. Under the theme "Taking Responsibility for Health in a Fragmenting World", the summit brings together leading minds from academia, politics, the private sector, and civil ...
more
- 2
New Label-Free Imaging Tracks Cancer Treatment in Single Cells
more Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...
moreAxolt Launches Brain Supplement to Combat Post-Pandemic Burnout Crisis
moreHagleitner Hygiene International GmbH
Global Hygiene Expert Pittet: Hand Hygiene Saves 5 to 8 Million Lives Each Year
moreLess than 30 days left to apply – don’t miss your chance
One documentmoreMedHub-AI and Terumo partner to market AI-based FFR in Japan
Tel Aviv, Israel (ots/PRNewswire) - MedHub-AI, pioneer of AI-based FFR "AutocathFFR" software, today announced a distribution agreement with Terumo Corporation to bring AutocathFFR®, its groundbreaking AI-powered Software as a Medical Device (SaMD), to the Japanese market. This partnership marks a new era in coronary physiology assessment where AI technology delivers superior confidence, reproducibility, and clinical ...
more